DURECT Co. (DRRX) Stake Increased by Ingalls & Snyder LLC

Ingalls & Snyder LLC increased its position in DURECT Co. (NASDAQ:DRRX) by 1.3% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 2,050,082 shares of the specialty pharmaceutical company’s stock after buying an additional 26,000 shares during the period. Ingalls & Snyder LLC owned 1.44% of DURECT worth $2,153,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Tocqueville Asset Management L.P. boosted its position in shares of DURECT by 59.8% in the first quarter. Tocqueville Asset Management L.P. now owns 808,500 shares of the specialty pharmaceutical company’s stock worth $849,000 after buying an additional 302,500 shares during the period. Wells Fargo & Company MN boosted its position in shares of DURECT by 152.3% in the first quarter. Wells Fargo & Company MN now owns 381,802 shares of the specialty pharmaceutical company’s stock worth $400,000 after buying an additional 230,500 shares during the period. Teachers Advisors LLC boosted its position in shares of DURECT by 16.0% in the fourth quarter. Teachers Advisors LLC now owns 224,361 shares of the specialty pharmaceutical company’s stock worth $301,000 after buying an additional 31,001 shares during the period. Broadfin Capital LLC boosted its position in shares of DURECT by 33.0% in the fourth quarter. Broadfin Capital LLC now owns 8,506,229 shares of the specialty pharmaceutical company’s stock worth $11,398,000 after buying an additional 2,111,023 shares during the period. Finally, Stonepine Capital Management LLC boosted its position in shares of DURECT by 32.3% in the fourth quarter. Stonepine Capital Management LLC now owns 2,177,791 shares of the specialty pharmaceutical company’s stock worth $2,918,000 after buying an additional 531,621 shares during the period. Hedge funds and other institutional investors own 49.04% of the company’s stock.

Institutional Ownership by Quarter for DURECT (NASDAQ:DRRX)

Shares of DURECT Co. (NASDAQ:DRRX) traded up 1.65% during trading on Friday, reaching $1.23. The company’s stock had a trading volume of 647,114 shares. The company’s 50 day moving average price is $0.97 and its 200 day moving average price is $1.11. DURECT Co. has a 12 month low of $0.74 and a 12 month high of $2.00. The firm’s market cap is $174.62 million.

DURECT (NASDAQ:DRRX) last issued its quarterly earnings results on Wednesday, May 10th. The specialty pharmaceutical company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06). The company had revenue of $4.57 million during the quarter, compared to analysts’ expectations of $3.60 million. DURECT had a negative return on equity of 220.58% and a negative net margin of 201.23%. On average, equities analysts predict that DURECT Co. will post ($0.23) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This report was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://transcriptdaily.com/2017/05/20/durect-co-drrx-stake-increased-by-ingalls-snyder-llc.html.

Separately, HC Wainwright restated a “buy” rating and set a $3.00 target price on shares of DURECT in a report on Thursday, March 16th.

About DURECT

Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.

12 Month Chart for NASDAQ:DRRX

Receive News & Ratings for DURECT Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply